Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
MRNA Analyst Ratings
Hold
2 Buy
13 Hold
4 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MRNA Stock 12 Month Forecast
Average Price Target
$47.06
▲(71.81% Upside)
| Highest Price Target$212.00 | Average Price Target$47.06 | Lowest Price Target$23.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
Reiterated
04/24/25
TD Cowen
Reiterated
04/23/25
Bernstein
Reiterated
04/22/25
William Blair
Reiterated
04/17/25
Leerink Partners
Reiterated
04/16/25
Jefferies
Reiterated
04/14/25
Morgan Stanley
Reiterated
04/09/25
RBC Capital
Reiterated
04/03/25
Brookline Capital Markets
Reiterated
03/31/25
Citi
Reiterated
03/26/25
J.P. Morgan
$40→$33
Sell
20.48%
Upside
Reiterated
03/21/25
Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA), Olympus (Other OTC: OCPNF) and Monte Rosa Therapeutics (NASDAQ: GLUE)
Berenberg Bank
$33→$30
Hold
9.53%
Upside
Reiterated
03/06/25
Moderna (MRNA) Receives a Hold from Berenberg Bank
DBS
$65→$35
Hold
27.78%
Upside
Reiterated
02/25/25
Analysts Conflicted on These Healthcare Names: Smith & Nephew Snats (NYSE: SNN), Dexcom (NASDAQ: DXCM) and Moderna (NASDAQ: MRNA)We have a HOLD rating on Moderna, with TP of US$35 We have a HOLD rating on Moderna, with TP of Covid-19 vaccine sales plummeting. Suffering from Covid-19 vaccine sales plummeting. Moderna grew to fame from the launch of its Covid- 19 vaccine Spikevax, which saw its product sales skyrocket from USD200mn in FY20 to USD18.4bn in FY22. However, with the easing of Covid-19 vaccine demand, Spikevax product sales fell 64% y/y to USD6.7bn in FY23. This dealt a huge blow to Moderna as >95% of its revenue was from Spikevax. This downtrend is expected to continue.
UBS
$96→$78
Buy
184.78%
Upside
Reiterated
02/19/25
Moderna price target lowered to $78 from $96 at UBSModerna price target lowered to $78 from $96 at UBS
Barclays
$111→$45
Hold
64.29%
Upside
Downgraded
02/18/25
Moderna downgraded to Equal Weight from Overweight at BarclaysModerna downgraded to Equal Weight from Overweight at Barclays
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
Reiterated
04/24/25
TD Cowen
Reiterated
04/23/25
Bernstein
Reiterated
04/22/25
William Blair
Reiterated
04/17/25
Leerink Partners
Reiterated
04/16/25
Jefferies
Reiterated
04/14/25
Morgan Stanley
Reiterated
04/09/25
RBC Capital
Reiterated
04/03/25
Brookline Capital Markets
Reiterated
03/31/25
Citi
Reiterated
03/26/25
J.P. Morgan
$40→$33
Sell
20.48%
Upside
Reiterated
03/21/25
Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA), Olympus (Other OTC: OCPNF) and Monte Rosa Therapeutics (NASDAQ: GLUE)
Berenberg Bank
$33→$30
Hold
9.53%
Upside
Reiterated
03/06/25
Moderna (MRNA) Receives a Hold from Berenberg Bank
DBS
$65→$35
Hold
27.78%
Upside
Reiterated
02/25/25
Analysts Conflicted on These Healthcare Names: Smith & Nephew Snats (NYSE: SNN), Dexcom (NASDAQ: DXCM) and Moderna (NASDAQ: MRNA)We have a HOLD rating on Moderna, with TP of US$35 We have a HOLD rating on Moderna, with TP of Covid-19 vaccine sales plummeting. Suffering from Covid-19 vaccine sales plummeting. Moderna grew to fame from the launch of its Covid- 19 vaccine Spikevax, which saw its product sales skyrocket from USD200mn in FY20 to USD18.4bn in FY22. However, with the easing of Covid-19 vaccine demand, Spikevax product sales fell 64% y/y to USD6.7bn in FY23. This dealt a huge blow to Moderna as >95% of its revenue was from Spikevax. This downtrend is expected to continue.
UBS
$96→$78
Buy
184.78%
Upside
Reiterated
02/19/25
Moderna price target lowered to $78 from $96 at UBSModerna price target lowered to $78 from $96 at UBS
Barclays
$111→$45
Hold
64.29%
Upside
Downgraded
02/18/25
Moderna downgraded to Equal Weight from Overweight at BarclaysModerna downgraded to Equal Weight from Overweight at Barclays
Best Analysts Covering Moderna
Which Analyst Should I Follow If I Want to Buy MRNA and Sell After:
1 Month
xxx
Success Rate
14/33 ratings generated profit
Average Return
-0.62%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.42% of your transactions generating a profit, with an average return of -0.62% per trade.
3 Months
xxx
Success Rate
17/33 ratings generated profit
Average Return
+9.88%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 51.52% of your transactions generating a profit, with an average return of +9.88% per trade.
1 Year
Success Rate
8/33 ratings generated profit
Average Return
-10.94%
reiterated a buy rating 3 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 24.24% of your transactions generating a profit, with an average return of -10.94% per trade.
2 Years
xxx
Success Rate
9/33 ratings generated profit
Average Return
+9.58%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 27.27% of your transactions generating a profit, with an average return of +9.58% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MRNA Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
6
6
4
4
2
Buy
0
0
0
0
0
Hold
19
22
20
23
21
Sell
7
12
13
13
10
Strong Sell
0
0
0
0
0
total
32
40
37
40
33
Each month's total comprises the sum of three months' worth of ratings.
MRNA Financial Forecast
MRNA Stock Forecast FAQ
What is MRNA’s average 12-month price target, according to analysts?
Based on analyst ratings, Moderna’s 12-month average price target is 47.06.
What is MRNA’s upside potential, based on the analysts’ average price target?
Moderna has 71.81% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MRNA a Buy, Sell or Hold?
Moderna has a consensus rating of Hold which is based on 2 buy ratings, 13 hold ratings and 4 sell ratings.
What is Moderna’s price target?
The average price target for Moderna is 47.06. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $212.00 ,the lowest forecast is $23.00. The average price target represents 71.81% Increase from the current price of $27.39.
The highest analyst price target is $212.00 ,the lowest forecast is $23.00. The average price target represents 71.81% Increase from the current price of $27.39.
What do analysts say about Moderna?
Moderna’s analyst rating consensus is a Hold. This is based on the ratings of 19 Wall Streets Analysts.
How can I buy shares of MRNA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.